GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » E10

Astellas Pharma (STU:YPH) E10 : €0.46 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Astellas Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Astellas Pharma's adjusted earnings per share data for the three months ended in Dec. 2024 was €-0.339. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.46 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Astellas Pharma's average E10 Growth Rate was -7.80% per year. During the past 3 years, the average E10 Growth Rate was 0.70% per year. During the past 5 years, the average E10 Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Astellas Pharma was 24.70% per year. The lowest was 0.70% per year. And the median was 5.70% per year.

As of today (2025-03-17), Astellas Pharma's current stock price is €9.22. Astellas Pharma's E10 for the quarter that ended in Dec. 2024 was €0.46. Astellas Pharma's Shiller PE Ratio of today is 20.04.

During the past 13 years, the highest Shiller PE Ratio of Astellas Pharma was 40.34. The lowest was 18.35. And the median was 23.20.


Astellas Pharma E10 Historical Data

The historical data trend for Astellas Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma E10 Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.60 0.62 0.59 0.48

Astellas Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.48 0.47 0.52 0.46

Competitive Comparison of Astellas Pharma's E10

For the Drug Manufacturers - General subindustry, Astellas Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Shiller PE Ratio falls into.



Astellas Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.339/110.7000*110.7000
=-0.339

Current CPI (Dec. 2024) = 110.7000.

Astellas Pharma Quarterly Data

per share eps CPI Adj_EPS
201503 0.074 97.900 0.084
201506 0.147 98.400 0.165
201509 0.200 98.500 0.225
201512 0.216 98.100 0.244
201603 0.110 97.900 0.124
201606 0.265 98.100 0.299
201609 0.199 98.000 0.225
201612 0.247 98.400 0.278
201703 0.160 98.100 0.181
201706 0.165 98.500 0.185
201709 0.147 98.800 0.165
201712 0.224 99.400 0.249
201803 0.086 99.200 0.096
201806 0.215 99.200 0.240
201809 0.195 99.900 0.216
201812 0.357 99.700 0.396
201903 0.131 99.700 0.145
201906 0.254 99.800 0.282
201909 0.313 100.100 0.346
201912 0.270 100.500 0.297
202003 0.027 100.300 0.030
202006 0.224 99.900 0.248
202009 0.097 99.900 0.107
202012 0.256 99.300 0.285
202103 -0.051 99.900 -0.057
202106 0.125 99.500 0.139
202109 0.170 100.100 0.188
202112 0.255 100.100 0.282
202203 -0.034 101.100 -0.037
202206 0.096 101.800 0.104
202209 0.277 103.100 0.297
202212 0.186 104.100 0.198
202303 -0.177 104.400 -0.188
202306 0.120 105.200 0.126
202309 -0.005 106.200 -0.005
202312 0.051 106.800 0.053
202403 -0.114 107.200 -0.118
202406 0.123 108.200 0.126
202409 0.126 108.900 0.128
202412 -0.339 110.700 -0.339

Add all the adjusted EPS together and divide 10 will get our e10.


Astellas Pharma  (STU:YPH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Astellas Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=9.22/0.46
=20.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Astellas Pharma was 40.34. The lowest was 18.35. And the median was 23.20.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Astellas Pharma E10 Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines